Drugs / PANK-003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06897228 | Feb 2024 → Jan 2027 expected | — | Shenzhen Celconta Life Science Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07043907 | Jul 2025 → Jul 2028 expected | non-small cell lung carcinoma | Shenzhen Celconta Life Science Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PANK-003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06897228 ↗ |
| Modality | Cell therapy | “PANK-003 cell injection(Peripheral blood-derived allogeneic natural killer cells )” NCT06897228 ↗ |